Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy

Last updated: October 25, 2010
Sponsor: Sanofi
Overall Status: Completed

Phase

3

Condition

Williams Syndrome

Vascular Diseases

Stress

Treatment

N/A

Clinical Study ID

NCT00956644
IRBAM_R_04220
  • Ages > 18
  • All Genders

Study Summary

Primary Objective:

  • To demonstrate that the antihypertensive efficacy of the fixed combination irbesartan/amlodipine 150/5 mg is superior to that of amlodipine 5 mg monotherapy in lowering systolic blood pressure (SBP) as measured by home blood pressure measurement (HBPM) after 5 weeks of treatment (W5)

Secondary Objective:

  • To compare the antihypertensive efficacy of the fixed combination irbesartan/amlodipine 150/5 mg with that of amlodipine 5 mg monotherapy after 5 weeks of treatment (W5)

  • To compare the antihypertensive efficacy of the fixed combination therapy irbesartan/amlodipine 150/10 mg with that of amlodipine 10 mg monotherapy at the end of treatment (W10)

  • To examine in each treatment group the change from week 5 to week 10 in SBP and diastolic blood pressure (DBP) assessed by HBPM and by office blood pressure measurement (OBPM)

  • To determine the incidence and severity of adverse events

Eligibility Criteria

Inclusion

Inclusion criteria:

  • Established essential hypertension

  • Treated with amlodipine 5 mg monotherapy for at least 4 weeks

  • With uncontrolled BP defined as mean SBP = or > 145 mmHg assessed by OBPM

  • Signed written inform consent obtained prior to inclusion in the study Randomisation Criteria:

  • Mean SBP = or > 135 mmHg assessed by HBPM

  • Good compliance with the HBPM protocol defined as at least 12 correct measurementsperformed over the last 6 days of the first period of measurements

  • Creatinine clearance = or > 30 ml/min, determined by Cockroft formula

Exclusion

Exclusion criteria:

  • Mean SBP = or > 180 mm Hg and/or mean DBP = or > 110 mm Hg measured at doctor's officeat Visit 1

  • Known or suspected causes of secondary hypertension

  • Patients with bilateral artery stenosis, renal artery stenosis in a solitary kidney,renal transplant or only one functioning kidney

  • Know contraindications or hypersensitivity to either amlodipine or irbesartan or tothe combination or history of angioedema related to the administration of anangiotensin II receptor antagonist or any combination of the drugs used

  • Known type 1 diabetes

  • Know severe hepatic impairment alanine aminotransferase (ALT) or aspartateaminotransferase (AST) > 5 times the upper limit of normal or history or hepaticencephalopathy, esophageal varices, or portocaval shunt

  • Known severe renal impairment (creatinine clearance < 30 ml/mn)

  • Concomitant use of any other antihypertensive treatment

  • Administration of any other investigational drug within 30 days before inclusion

  • Inability to obtain a valid automatic BP measurement recording

  • Presence of any severe medical or psychological condition that, in the opinion of theinvestigator, indicate that participation in the study is not in the best interest ofthe patient

  • Presence of any other conditions (e.g.: geographical, social, etc) that would restrictor limit the patient participation for the duration of the study

  • Pregnant or breast feeding women

  • Women of childbearing potential unable or unwilling to use an acceptable method toavoid pregnancy for the entire study period The above information is not intended to contain all considerations relevant to a patient'spotential participation in a clinical trial.

Study Design

Total Participants: 406
Study Start date:
July 01, 2009
Estimated Completion Date:
August 31, 2010

Connect with a study center

  • Sanofi-Aventis Investigational Site Number 07602

    Campinas, 13059-900
    Brazil

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 076-005

    Rio de Janeiro, 20551-030
    Brazil

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 07605

    Rio de Janeiro, 20551-030
    Brazil

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 07604

    São José, 88103-460
    Brazil

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 076-004

    São Paulo, 04038-002
    Brazil

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 07604

    São José, 88103-460
    Brazil

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 076-002

    São Paulo, 05403-000
    Brazil

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 076-004

    São Paulo, 04038-002
    Brazil

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 07601

    São Paulo, 04025-011
    Brazil

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 07603

    São Paulo, 05403-000
    Brazil

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 15202

    Santiago,
    Chile

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 15203

    Santiago,
    Chile

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 15204

    Santiago,
    Chile

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 15205

    Santiago,
    Chile

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 15206

    Santiago,
    Chile

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 17003

    Barranquilla,
    Colombia

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 17004

    Barranquilla,
    Colombia

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 17002

    Medellin,
    Colombia

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 81803

    Alexandria,
    Egypt

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 81804

    Alexandria,
    Egypt

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 81801

    Cairo,
    Egypt

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 81802

    Cairo,
    Egypt

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 42202

    Beirut,
    Lebanon

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 42203

    Beirut,
    Lebanon

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 42204

    Beirut,
    Lebanon

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 42205

    Beirut,
    Lebanon

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 42206

    Beirut,
    Lebanon

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 48401

    Durango, 34080
    Mexico

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 48402

    Guadalajara, 44656
    Mexico

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 48403

    Guadalajara, 44656
    Mexico

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 48404

    Guadalajara, 44680
    Mexico

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 48406

    Guadalajara, 44670
    Mexico

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 48405

    Mexico, 06140
    Mexico

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 48407

    Mexico, 07330
    Mexico

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 50401

    Casablanca,
    Morocco

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 50402

    Marrakech,
    Morocco

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 50403

    Marrakech,
    Morocco

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 78804

    Ariana,
    Tunisia

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 78803

    Monastir, 5000
    Tunisia

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 78802

    Sfax,
    Tunisia

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 78801

    Tunis,
    Tunisia

    Site Not Available

  • Sanofi-Aventis Investigational Site Number 86201

    Caracas,
    Venezuela

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.